Use of anti-phosphohistone H3 immunohistochemistry to determine mitotic rate in thin melanoma

American Journal of Dermatopathology

Volumn 32, Issue 7, 2010, Pages 650-654

  Casper, David J ^a   Ross, Kate I ^a,b   Messina, Jane L ^a   Sondak, Vernon K ^c   Bodden, Cheryl N ^a   McCardle, Tim W ^c   Glass, L Frank ^a,c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b FLORIDA STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

immunohistochemistry; melanoma; melanoma staging; mitotic rate; phosphohistone H3

Indexed keywords

EOSIN; HEMATOXYLIN; HISTONE ANTIBODY; PHOSPHOHISTONE H3 ANTIBODY; SERINE DERIVATIVE; UNCLASSIFIED DRUG; HISTONE;

ARTICLE; CANCER STAGING; CELL LABELING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOCYTE; MELANOMA; MITOSIS RATE; PRIORITY JOURNAL; TISSUE SECTION; METABOLISM; METHODOLOGY; MITOSIS; MITOSIS INDEX; PATHOLOGY; SKIN TUMOR;

HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; MITOSIS; MITOTIC INDEX; NEOPLASM STAGING; SKIN NEOPLASMS;

EID: 77957327970     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/DAD.0b013e3181cf7cc1     Document Type: Article

References (27)

1. Azzola MF, Shaw HM, Thompson JF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer. 2003;97:1488-1498.
2. Barnhill RL, Katzen J, Spatz A, et al. The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. J Cutan Pathol. 2005;32:268-273.
3. Francken AB, Shaw HM, Thompson JF, et al. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol. 2004;11:426-433.
4. Attis MG, Vollmer RT. Mitotic rate in melanoma: a reexamination. Am J Clin Pathol. 2007;127:380-384.
5. McGovern VJ, Cochran AJ, Van der Esch EP, et al. The classification of malignant melanoma, its histological reporting and registration: a revision of the 1972 Sydney classification. Pathology. 1986;18:12-21.
6. Scolyer RA, Shaw HM, Thompson JF, et al. Interobserver reproducibility of histopathologic prognostic variables in primary cutaneous melanomas. Am J Surg Pathol. 2003;27:1571-1576.
7. Brochez L, Verhaeghe E, Grosshans E, et al. Inter-observer variation in the histopathological diagnosis of clinically suspicious pigmented skin lesions. J Pathol. 2002;196:459-466.
8. Colloby PS, West KP, Fletcher A. Observer variation in the measurement of Breslow depth and Clark's level in thin cutaneous malignant melanoma. J Pathol. 1991;163:245-250.
9. Corona R, Mele A, Amini M, et al. Interobserver variability on the histopathologic diagnosis of cutaneous melanoma and other pigmented skin lesions. J Clin Oncol. 1996;14:1218-1223.
10. Murali R, Hughes MT, Fitzgerald P, et al. Interobserver variation in the histopathologic reporting of key prognostic parameters, particularly clark level, affects pathologic staging of primary cutaneous melanoma. Ann Surg. 2009;249:641-647.
11. Colman H, Giannini C, Huang L, et al. Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas. Am J Surg Pathol. 2006;30:657-664.
12. Ribalta T, McCutcheon IE, Aldape KD, et al. The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria. Am J Surg Pathol. 2004;28:1532-1536.
13. Nasr MR, El-Zammar O. Comparison of pHH3, Ki-67, and surviving immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol. 2008;30:117-122.
14. O'Rourke N, Hatcher L, Stepanski EJ. A Step-by-Step Approach to Using SAS for Univariate & Multivariate Statistics. 2nd ed. New York: Wiley Interscience; 2005.
15. Paek SC, Griffith KA, Johnson TM, et al. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer. 2007;109:100-108.
16. Kesmodel SB, Karakousis GC, Botbyl JD, et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol. 2005;12:449-458.
17. Sondak VK, Taylor JM, Sabel MS, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol. 2004;11: 247-258.
18. Schmoeckel C, Braun-Falco O. Prognostic index in malignant melanoma. Arch Dermatol. 1978;114:871-873.
19. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-6206.
20. Tapia C, Kutzner H, Mentzel T, et al. Two mitosis-specific antibodies, MPM-2 and phospho-histone H3 (Ser28), allow rapid and precise determination of mitotic activity. Am J Surg Pathol. 2006;30:83-89.
21. Veras E, Malpica A, Deavers MT, et al. Mitosis-specific marker phosphohistone H3 in the assessment of mitotic index in uterine smooth muscle tumors: a pilot study. Int J Gynecol Pathol. 2009;28:316-321.
22. Hirata A, Inada K, Tsukamoto T, et al. Characterization of a monoclonal antibody, HTA28, recognizing a histone H3 phosphorylation site as a useful marker of M-phase cells. J Histochem Cytochem. 2004;52: 1503-1509.
23. Ajiro K, Nishimoto T. Specific site of histone H3 phosphorylation related to the maintenance of premature chromosome condensation. Evidence for catalytically induced interchange of the subunits. J Biol Chem. 1985;260: 15379-15381.
24. Goto H, Tomono Y, Ajiro K, et al. Identification of a novel phosphorylation site on histone H3 coupled with mitotic chromosome condensation. J Biol Chem. 1999;274:25543-25549.
25. Hendzel MJ, Wei Y, Mancini MA, et al. Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma. 1997;106:348-360.
26. Li DW, Yang Q, Chen JT, et al. Dynamic distribution of Ser-10 phosphorylated histone H3 in cytoplasm of MCF-7 and CHO cells during mitosis. Cell Res. 2005;15:120-126.
27. Shibata K, Inagaki M, Ajiro K. Mitosis-specific histone H3 phosphorylation in vitro in nucleosome structures. Eur J Biochem. 1990;192: 87-93.